Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.69 |
| ▸ | IGF1R | P08069 | 13/20 | 0.69 |
| ▸ | ERBB3 | P21860 | 13/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 13/20 | 0.69 |
| ▸ | BTK | Q06187 | 5/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4826510 | 0.92 | EGFR (0.57) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL4826042 | 0.91 | EGFR (0.57) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL4826144 | 0.90 | EGFR (0.58) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL7045402 | 0.87 | EGFR (0.55) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL7047600 | 0.85 | EGFR (0.52) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL14268429 | 0.84 | EGFR (0.79) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6222127 | 0.83 | EGFR (0.79) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6222131 | 0.83 | EGFR (0.79) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL4818658 | 0.82 | EGFR (0.62) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6431591 | 0.82 | EGFR (1.00) | EGFRERBB2IGF1RERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | EGFR 818/4885ERBB2 894/4885IGF1R 4007/4885 |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | EGFR 1992/4885ERBB2 682/4885IGF1R 1680/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | EGFR 2229/4885ERBB2 529/4885IGF1R 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.